Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
February 07, 2025 10:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim SMID Cap Biotech Conference
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
January 13, 2025 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 12, 2024 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
November 06, 2024 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 29, 2024 07:46 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024 07:45 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 11, 2024 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 04, 2024 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024 17:21 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results